Women’s Health and Artificial Intelligence: Advancing Precision in Perinatal Mental Health
Brisbane, Australia – January 6, 2026 – A recent editorial in Women’s Health and Artificial Intelligence published by JAMA Internal Medicine highlights the growing importance of applying artificial intelligence thoughtfully and equitably to address long-standing gaps in women’s health.
The editorial underscores a stark reality: women spend approximately 25% more of their lives in poor health compared to men. It argues that AI-driven approaches, when designed with fairness and representation in mind, have the potential to uncover sex- and gender-specific biomarkers, disease patterns, and treatment responses that traditional research paradigms may have overlooked.
This perspective aligns closely with Ketim Technologies’ mission to advance precision psychiatry in maternal mental health. In perinatal care, spanning pregnancy through postpartum, clinical presentation is often heterogeneous, symptom onset can vary significantly, and biological signals may not align neatly with existing screening frameworks. Addressing these complexities requires robust data integration across biomarkers, clinical context, and longitudinal outcomes.
Ketim’s research program and planned in vitro diagnostic (IVD) development for postpartum depression risk prediction are built on this foundation: combining proteomic biomarker discovery with advanced AI-driven analytics, while embedding rigorous approaches to fairness, bias mitigation, and representative cohort analysis.
“Health technologies should not be built around the ‘average patient,’” said Dr. Clarissa Yates. “They must reflect the biological and lived diversity of women across life stages, particularly during vulnerable transitions such as the perinatal period.”
Ketim is preparing to showcase its AI analytical platform, developed under the leadership of Co-Founder Dr. Maciej Trzaskowski, which integrates bias-aware modelling and clinically contextualised biomarker interpretation to support robust IVD development.
As global conversations around AI in healthcare accelerate, Ketim remains committed to ensuring that advances in precision medicine meaningfully address the women’s health gap.
For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au
